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Abstract 
Background: Functionalized nanoparticles (NPs) are one promising tool for detecting specific molecular targets and 
combine molecular biology and nanotechnology aiming at modern imaging. We aimed at ligand‑directed delivery 
with a suitable target‑biomarker to detect early pancreatic ductal adenocarcinoma (PDAC). Promising targets are 
galectins (Gal), due to their strong expression in and on PDAC‑cells and occurrence at early stages in cancer precursor 
lesions, but not in adjacent normal tissues.
Results: Molecular probes (10‑29 AA long peptides) derived from human tissue plasminogen activator (t‑PA) were 
selected as binding partners to galectins. Affinity constants between the synthesized t‑PA peptides and Gal were 
determined by microscale thermophoresis. The 29 AA‑long t‑PA‑peptide‑1 with a lactose‑functionalized serine 
revealed the strongest binding properties to Gal‑1 which was 25‑fold higher in comparison with the native t‑PA 
protein and showed additional strong binding to Gal‑3 and Gal‑4, both also over‑expressed in PDAC. t‑PA‑peptide‑1 
was selected as vector moiety and linked covalently onto the surface of biodegradable iron oxide nanoparticles (NPs). 
In particular, CAN‑doped maghemite NPs (CAN‑Mag), promising as contrast agent for magnetic resonance imaging 
(MRI), were selected as magnetic core and coated with different biocompatible polymers, such as chitosan (CAN‑
Mag‑Chitosan NPs) or polylactic co glycolic acid (PLGA) obtaining polymeric nanoparticles (CAN‑Mag@PNPs), already 
approved for drug delivery applications. The binding efficacy of t‑PA‑vectorized NPs determined by exposure to dif‑
ferent pancreatic cell lines was up to 90%, as assessed by flow cytometry. The in vivo targeting and imaging efficacy 
of the vectorized NPs were evaluated by applying murine pancreatic tumor models and assessed by 1.5 T magnetic 
resonance imaging (MRI). The t‑PA‑vectorized NPs as well as the protease‑activated NPs with outer shell decoration 
(CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac) showed clearly detectable drop of subcutaneous and orthotopic 
tumor staining‑intensity indicating a considerable uptake of the injected NPs. Post mortem NP deposition in tumors 
and organs was confirmed by Fe staining of histopathology tissue sections.
Conclusions: The targeted NPs indicate a fast and enhanced deposition of NPs in the murine tumor models. The 
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac interlocking steps strategy of NPs delivery and deposition in pancre‑
atic tumor is promising.
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Background
At present, no reliable method is available which allows 
for early diagnosis of pancreatic cancer. Clinically availa-
ble imaging modalities lack the sensitivity and specificity 
to diagnose asymptomatic pancreatic cancer and precur-
sor lesions. This uncertainty leads to a postponement 
of surgical intervention for months, during which time 
often incurable tumors may arise from precursor lesions 
or small premalignant foci [1]. Early detection is the only 
promising approach to significantly improve the survival 
of patients with pancreatic cancer. Non-invasive tools for 
the diagnosis and monitoring of this disease are of urgent 
need.
Tumor associated antigens, if highly expressed intra-
cellularly or at the cell surface of pancreatic cancer cells, 
were suggested to be ideal targeting proteins for tumor-
size quantification. Ideally, these antigens need to be 
present already at early tumor stages and not, or only in 
negligible amounts, in the tumor-neighboring tissues. 
Increasing evidence exists that galectins have important 
functions in several aspects of cancer biology [2] includ-
ing pancreatic cancer [3]. They contribute to neoplastic 
transformation, tumor cell survival, angiogenesis and 
tumor metastasis. Galectins are present both inside and 
outside cells, and function both intracellularly and extra-
cellularly. There is direct evidence that galectin-1 and 
galectin-3 expression is necessary for the initiation of the 
transformed phenotype of tumors [4]. The mechanisms 
by which galectins are involved in cell transformation are 
not yet fully understood, but both galectin-1 and galec-
tin-3 can interact with oncogenic Ras [5–7]. Recently it 
was shown that galectin-1 (Gal-1) is a functional tissue 
plasminogen activator (tPA) -receptor participating in 
PDAC progression with high specificity and strong affin-
ity and therefore provides a promising therapeutic strat-
egy for this cancer [8]. Gal-1 was studied here because 
it is strongly expressed in PDAC cells and tumoral 
fibroblasts, and plays a crucial role in PDAC-associated 
desmoplasia, a main hallmark of pancreatic cancer. 
Expression of galectins is known to be upregulated in 
PDAC [9] but, more importantly, not expressed in adja-
cent normal tissues [9, 10]. Because the overexpression of 
galectins already occurs under inflammatory conditions 
and early stages of cancer in pancreatic cancer precur-
sor lesions, PanINs [11] the proteins have the potential of 
marking cells prior to their development into cancerous 
lesions [12]. Therefore, galectins may be good receptors 
to bind and to accumulate ligand-decorated nanoparti-
cles in pancreatic cancer cells and thus allow imaging and 
therapeutic tumor targeting.
Iron oxide nanoparticles received great attention due to 
their potential application as safe and non-toxic contrast 
agent for magnetic resonance imaging and have been 
applied in early diagnosis of cancerous lesions [13] The 
possibility to coat them with biodegradable and biocom-
patible polymers suitable for drug delivery applications 
is particularly appealing since it allows their administra-
tion within the body with reduction of side-effects and 
enhancement of tumor uptake [14]. Chitosan [15] and 
poly(lactic-co-glycolic acid) [16] are both able to form 
nanostructures and to entrap iron oxide nanoparticles. In 
this study we decided to test the two systems in order to 
evaluate their efficacy in delivery of nanoparticles.
Due to the leaky vasculature and the poor lymphatic 
drainage of tumors, NPs can selectively accumulate in 
the tumor tissue [17, 18]. They can convey additional 
ligands for active targeting, whereby moieties can bind 
with receptors overexpressed and presented on the sur-
face of cancer cells [19]. The targeting ligands enable not 
only the specific nanoparticle-cancer cell interactions, 
but also promote internalization by receptor-mediated 
endocytosis.
The purposes of this study were to determine the galec-
tins Gal-1, Gal-3 and Gal-4 known to be overexpressed in 
pancreatic cancers as targets and to investigate a poten-
tial ligand tPA-derived peptide as receptor/ligand bind-
ing partner. The biodegradable CAN-Mag-Chitosan-PEG 
and maghemite-loaded PLGA-PEG-COOH based poly-
meric nanoparticles (CAN-Mag@PNPs) were selected 
as nano-Fe-delivery systems and functionalized with the 
t-PA-peptide-1 with a lactose-linked serine. We further 
tested the concept of protease-activated NPs by addition 
of an outer protective PEG-shell [20]. The proteolytically 
cleavable outer PEG-shell allows to overcome the scav-
enging properties by the immune system and enables 
an escape from the monocyte phagocytic system (MPS). 
With this the CAN-Mag@PNPs-PEG-REGAcp-PEG/
tPApep1Lac NPs reside for extended time in the blood 
circulation, can more efficiently penetrate through the 
interstitial tumor microenvironment [21]. The presence 
of matrix metalloproteinases in the tumor microenvi-
ronment specifically activated the NPs binding to tumor 
cell surface receptors by de-shielding the NP and thus 
promoted the linkage of tPA-peptide1-vectorized NPs 
to cells by ligand-receptor (tPA-Gal) interaction. Here 
we show that the investigated tPA-peptide1-vectorized 
NPs efficiently bind and accumulate on tumor cells and 
stroma which allows already small tumor size detection 
and imaging.
Results
Galectin expression
Tumor associated antigens, which are selectively over-
expressed in PDAC cells and particularly already at 
early stages are ideal target proteins for early detec-
tion and tumor targeting. Based on previous work of 
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our laboratory [9, 10] and others [3, 8, 22] we proved 
first the suitability of the proposed galectins as targets, 
and identified suitable cell lines for the experimen-
tal analysis, as well as selected ligands interacting with 
the galectins. For this purpose eight human pancreatic 
cancer cell (PaCa) lines were tested for the expression 
of galectin-1 at the mRNA and protein levels. Gal-1 was 
detected in all PaCa cells, however, the highest Gal-1 
expression on mRNA and protein level were found 
in MiaPaca-1, Panc-1 and Su.86.86 cells as shown in 
Table 1 and Fig. 1.
Two cell lines Panc-1 and Su.86.86 were selected for 
subsequent studies.
The expression of Gal-1 was also assessed by immu-
nohistochemistry in human PDAC-tissue. Gal-1 which 
is a 14  kDa protein was highly expressed intracellularly 
and on the cell surface in human PaCa cell lines and in 
PDAC-tissues. Strong staining, particularly in epithelial 
cells and stroma occurred likely due to Gal-1 secretion 
from cancer cells Fig.  2a. Additionally to human PDAC 
the expression of our target proteins Gal-1, Gal-3 and 
Gal-4 was confirmed in the below described subcutane-
ous and orthotopic tumor mouse models with human 
Panc-1 and Su.86.86 cells (Fig. 2b–d).
t‑PA‑peptides: interaction studies of galectins with t‑PA 
by thermophoresis
To investigate the binding efficiency of the short t-PA-
ligands [10 to 29-AA-long peptides fluorescein or rho-
damine-labelled] to galectin-1, we applied the microscale 
thermophoresis (MST) technology which allows quan-
titative analysis of protein interactions in solutions. By 
using MST, individual affinity constants between the dif-
ferent t-PA peptides and galectins (Gal-1, -3, -4) previ-
ously characterized to be over-expressed in PDAC were 
determined and compared to the recombinant human 
t-PA protein (rh t-PA) as presented in Table 2.
Peptide-1 (AA position 137-164) in the native t-PA with 
additional glycosylation (lactose) and C-terminal fluores-
cein-labeled lysine showed the strongest binding proper-
ties to Gal-1. The binding was 25-times higher compared 
to that of rh t-PA. Therefore this molecule was employed 
as targeted moiety and for the manufacture of NPs for 
pancreatic tumor targeting. The 29 AA long sequence of 
the t-PApep-1Lac is here presented: GTWSTAESGAE-
CTNWXSSALAQKPYSGRK (X  =  Ser(β-d-lactose) and 
the free amino- and carboxy-terminal groups of the pep-
tide were used as the linkage to the NPs. The side-chain 
of the C-terminal lysine (K) was additionally fluorescein 
labelled for monitoring studies.
On the basis of the affinity constants between the dif-
ferent t-PApep-1 and galectins (Table 2), we next assessed 
the cell-binding properties of NPs, functionalized with 
the t-PApep1Lac.
Nanoparticles
The as-synthesized cerium cation-doped and chitosan-
functionalized γ-Fe2O3 maghemite (CAN-Mag-Chitosan) 
NPs were further functionalized with PEG species of 2 
and/or 5 kDa molecular weight chains. For this purpose, 
mono- and bis-amine-end-capped PEGs were mixed 
with chitosan-functionalized CAN-Mag NPs in the pres-
ence of divinylsulfone (DVS) that acted as a reactive 
linker between amine-functionalized NPs surface and 
PEG chain ends (Fig.  3a). To further decorate NPs with 
t-PA, a carboxylic acid group of the t-PA peptide was 
activated by EDC prior to the addition to amine-func-
tionalized magnetic NPs. TEM images of chitosan and 
chitosan-PEG-modified CAN-Mag NPs are presented in 
Fig.  3b, c. The grafted polymers are seen as fibres con-
nected between the NPs. The characteristics of different 
t-PA-vectorized CAN-Mag-Chitosan-PEG NPs are also 
detailed in Table 3.
The DLS hydrodynamic diameters of these highly posi-
tively charged particles (ζ potential +20 to 34 mV range) 
are in a 150–270 nm range. Iron concentration in tested 
Table 1 mRNA-expression of galectin-1 for the eight hPaCa cell lines
a QRT-PCR data: adjusted to 1 × 104 copies of cyclophylin B
Cell line AsPc‑1 BxPC‑3 Capan‑1 Colo‑357 MiaPaca‑2 Panc‑1 Su.86.86 T3M4
mRNA copiesa 9301 1432 3838 3666 34,314 36,742 17,498 2550
Fig. 1 Expression of galectin‑1 (Gal‑1) protein in eight human PDAC 
cell lines. The immunoblot shows the highest Gal‑1 expression in 
MiaPaca‑2, Panc‑1 and Su.86.86 cells
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Fig. 2 IHC confirms overexpression of galectins (Gal‑1, ‑3, ‑4) in pancreatic tumors. a Human pancreatic ductal adenocarcinoma (Hu PDAC);  
b Murine (Mu) orthotopic (ot) and subcutaneous (s.c.) tumors of Panc‑1 and c orthotopic and subcutaneous Su.86.86 tumors of nude mice. Some 
representative galectin‑1, ‑3, ‑4 stained areas (cytosolic, membraneous and stroma) are indicated by arrows
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dispersions was determined by inductively coupled 
plasma atomic absorption spectroscopy (ICP-AES).
For the synthesis of the second nanostructure the 
CAN-maghemite nanoparticles were coated onto their 
surface with an organic ligand in order to ensure lipo-
philicity instead of hydrophilicity [23], then they were 
entrapped into polymeric nanoparticles (PNPs) made up 
of poly(lactic-co-glycolic)-co-polyethylene glycol copol-
ymer [24, 25]. The as-synthesized CAN-Mag@PNPs 
showed good features and a negative ζ-potential due to 
the presence in the outer shell of deprotonated carbox-
ylic acid groups derived from the free end of the PEG 
fragment. The presence of these groups allowed for the 
CAN-Mag@PNPs surface functionalization with tPApep-
1Lac peptide or PEG-REGAcp-PEG agent. After activa-
tion of carboxylic acid groups with EDC and Sulfo-NHS, 
the desired peptide (or both of these) was introduced 
in the reaction mixture so that an amidation reac-
tion between the activated acid and a residual terminal 
amine function in the peptide took place. Following this 
procedure CAN-Mag@PNPs-tPApep1Lac, CAN-Mag@
PNPs-PEG-REGAcp-PEG and CAN-Mag@PNPs-PEG-
REGAcp-PEG/tPA-pep1Lac were obtained. All the prod-
ucts were characterized by means of DLS for size and 
ζ-potential analysis, AAS for iron amount estimation, 
gravimetric analysis for dry matter (iron  +  polymer) 
determination and Bradford test for the determination of 
peptide amount conjugated on the outer shell. Results are 
reported in Table 3 and the entire procedure is schemati-
cally presented in Fig. 3d.
Binding efficiency of functionalized NPs to pancreatic 
cancer cell lines
With the first flow cytometry experiments we analyzed 
the nanoparticle-core (Core CAN-maghemite (Ce-Fe2O3) 
and the t-PA-peptide1-lactose (t-PApep1lac) linked to 
the core. This was to determine whether the fluorescein-
labelled t-PA-peptides, covalently linked to NPs, bind to 
Panc-1 and Su86.86 cells and if the cells are able to inter-
nalize the NPs. In a parallel set of experiments the bind-
ing of the t-PA-peptide alone (without linkage to NPs) to 
the pancreatic cancer cells was assessed. For the experi-
mental set-up a concentration of t-PA peptide of 1.25 µM 
was applied and the cells were exposed to the NPs with 
and without peptides for different incubation periods of 
2, 6, 12 and 24 h. Our analysis revealed that the t-PA-pep-
tides linked to nanoparticles bind with a lower efficiency 
to the cells in comparison with the binding of peptides 
without linkage.
Further analysis showed that the physicochemi-
cal properties of the NPs and the investigated cell lines 
revealed strong influences on binding efficacies. It turned 
out that only a minor fraction (0.5%) of the negative con-
trol NP, namely CAN-Mag@PNPs, showed fluorescence. 
In contrast, the functionalized nanoparticle CAN-Mag@
PNPs-tPApep1Lac showed up to 90% fluorescence (due to 
the fluorescein linked to t-PApep1Lac). These results are 
in line with good linkage-stability as shown in Table 4.
The highest binding of the vectorized NPs was reached 
at 6–12  h exposure. Interestingly, it was observed that 
strong binding (even to the cell line T3M4, results not 
shown) occurred indicating that other binding partners 
(receptors) are present on these cells. We identified, addi-
tionally to Gal-1, the Gal-3 and Gal-4 as binding can-
didates and confirmed the flow cytometry analysis by 
microscale thermophoresis (MST) experiments and IHC 
(Table 2, Fig. 2).
As a NPs internalization criterion we used the iron 
uptake determination. A time-dependent exposure of 
NPs to cells and subcellular fractionation showed also 
different results depending on cell line and exposure 
time. Nevertheless, for non-vectorized NPs the highest 
Table 2 Binding constants (KD) of  t-PA-peptide-1 and  its 
derivates with galectins Gal-1, Gal-3 and Gal-4
The MST was performed with the tPA peptide and its variants (N- or C-terminal 
fluorescence-labeled and glycosylated forms) in the presence of human 
galectins
Italic values indicate significance of p < 0.01
T‑PA 
peptide
Label Modification Galectin KD [µM] Fold diff.
rh t‑PA 
protein
N‑Fluo. None = (Asn16) Gal‑1 4.92 1
Peptide‑
1(pep‑1)
N‑Fluo. None Gal‑1 141.1 −28.7
t‑PA‑
pep‑1
C‑Fluo. None Gal‑1
t‑PA‑pep‑
1gal
C‑TAMRA Ser16‑αd‑
galactose
Gal‑1 0.66 7.5
t‑PA‑pep‑
1lac
N‑Fluo. Ser16‑βd‑lactose Gal‑1 0.286 17
t‑PA‑pep‑
1lac
C‑Fluo. Ser16‑βd‑lactose Gal‑1 0.20 25
rh t‑PA 
protein
N‑Fluo. None = (Asn16) Gal‑3 7.68 1
t‑PA‑
pep‑1
N‑Fluo. None Gal‑3 272.0 −35.4
t‑PA‑pep‑
1gal
C‑TAMRA Ser16b‑αd‑
galactose
Gal‑3 39.1 −5.1
t‑PA‑pep‑
1lac
C‑Fluo. Ser16b‑βd‑
lactose
Gal‑3 0.73 10.4
rh t‑PA 
protein
N‑Fluo. none = (Asn16) Gal‑4 51.2 1
t‑PA‑
pep‑1
N‑Fluo. none Gal‑4 34.0 1.5
t‑PA‑pep‑
1gal
C‑TAMRA Ser16‑βd‑
galactose
Gal‑4 211 −4.2
t‑PA‑pep‑
1lac
C‑Fluo. Ser16‑βd‑lactose Gal‑4 12.7 4.03
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Fig. 3 a–d Nanoparticle synthesis: a synthetic route to t‑PA decoration of both CAN‑Mag‑Chitosan and CAN‑Mag‑Chitosan‑PEG NPs. TEM micro‑
photographs of t‑PA‑decorated (b) CAN‑Mag‑Chitosan and (c) CAN‑Mag‑Chitosan‑PEG NPs. d Schematic presentation of the preparation of the final 
nanosystem CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac
Table 3 Characterization of nanosystems
Nanosystem Diameter [nm] PDI ζ‑potential [mV] Iron [mg/ml] Dry matter [mg/ml] tPApep1lac [µM]
CAN‑Mag‑Chitosan‑tPApep1Lac PEG 
2 kDa
191.6 ± 1.5 0.44 ± 0.03 34.2 0.45 2.74 38.4
CAN‑Mag‑Chitosan‑tPApep1Lac PEG 
2&5 kDa
266 ± 0.5 0.46 ± 0.03 31.3 0.45 3.8 60.1
CAN‑Mag‑Chitosan‑tPApep1Lac PEG 
5 kDa
156 ± 2 0.429 ± 0.02 21.4 0.48 8.8 37.4
CAN‑Mag@PNPs‑tPApep1Lac 125.4 ± 1.8 0.133 ± 0.012 −15.4 0.636 6.0 12.9
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG 118.6 ± 1.2 0.140 ± 0.004 −18.4 0.50 5.9 –
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/
tPApep1Lac
114.7 ± 2.9 0.196 ± 0.004 −5.8 0.641 6.6 31.7
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Fe levels were found in the cytoskeleton fraction (45.9%) 
followed by the cell culture media fraction (39%), whereas 
for the tPA-pep1lac-vectorized NPs, most of the iron (up 
to 88%) after 6 h exposure was measured in the membra-
neous fractions (Table 5).
De‑shielding mechanism for the NPs: MMP‑targeted NPs 
delivery
Elevated expression of MMP-9 is associated with can-
cerous and inflammatory microenvironments, includ-
ing PDAC [26]. We aimed to use the presence of active 
MMP-9 in the tumor microenvironment to potentiate 
targeted delivery and infiltration of NPs into the tumor 
tissue of pancreatic cancer patients. Therefore we evalu-
ated (here in vitro) the presence and activity of MMP-9 
with a focus on the development of protease-modifiable 
nanoparticles [20]. For this purpose a cleavable peptide 
(named REGAcp) derived from collagen II as an optimal 
substrate for MMP-9 was designed and a Polyethylene-
glycol-REGAcp-Polyethyleneglycol (PEG-REGAcp-PEG) 
chain was synthesized and covalently linked to NPs.
Incubation experiments with active MMP-9 indicated 
the de-shielding mechanism for the NPs. In this context 
we used MMP-9 as a tool to unmask the NPs and make 
these locally effective in the tumor cell vicinity. Applying 
the NPs CAN-Mag@PNPs-t-PApep1Lac, and the shielded 
CAN-Mag@PNPs-PEG-REGAcp-PEG/tPA-pep1Lac we 
aimed to elucidate the binding efficiency of three modali-
ties as presented in Fig. 4.
The results revealed that NPs with outer shell decora-
tion (CAN-Mag@PNPs-PEG-REGAcp-PEG/tPA-pep-
1Lac) bind poorly (2.3% of the gated cells). A short (2  h) 
preincubation of such particles with MMP-9 showed no 
enhancing effect. An extended MMP-9 pre-incubation 
step in the presence of its activator cdMMP-3 for 24  h 
slightly elevated the binding (3.4–7.8%) of the NPs which 
was only 8.2% compared to the CAN-Mag@PNPs-tPApe-
p1Lac NPs (Table 4). The artificial simulation of the in vivo 
situation here demonstrated that an extended preactiva-
tion phase (deshielding step) is necessary for better bind-
ing of the particles to cells as measured by flow cytometry.
In vivo pancreatic tumor targeting efficacy using MRI in a 
mouse xenograft model
We next evaluated the efficacy of NPs accumulation 
using xenograft models of pancreatic cancer developed 
Table 4 Flow cytometry analysis
Percentage of cells labeled with nanoparticles (NPs) after 2, 12 and 24 h incubation time. The NP binding was dependent on the NPs composition, the exposure time 
and cell lines tested
Nd not determined
Nanoparticle formulation Panc‑1 Su.86.86
2 h 12 h 24 h 2 h 12 h 24 h
t‑PApep1Lac 2.6 87.6 86.3 25.7 45.8 36.6
CAN‑Mag@PNPs ‑tPApep1Lac 37.3 85.2 74.3 Nd Nd Nd
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPApep1Lac 1.4 2.2 1.8 0.3 0.5 0.9
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPApep1Lac + MMP9 2.2 Nd 4.1 2.9 4.3 7.8
CAN‑Mag‑Chitosan–tPApep1Lac 30.5 63.3 55.3 Nd Nd Nd
CAN‑Mag‑Chitosan‑tPApep1Lac PEG 2 kDa 48.3 52.3 53.5 90.1 91.7 93.7
CAN‑Mag‑Chitosan–tPApep1Lac PEG 2&5 kDa 21.8 62.4 68.3 68.9 85.8 79.5
CAN‑Mag‑chitosan–tPApep‑1Lac PEG 5 kDa 19.5 81.9 86.7 26.3 65.2 66.0
Table 5 Representative iron-distribution in  subcellular fractions after  6  h NPs (500  µg Fe) treatment of  Su.86.86 cells 
(2 × 106 cells in 10 cm culture dish)
a CAN-Mag-Chitosan PEG 2 and 5 kDa
b CAN-Mag-Chitosan–tPApep1Lac PEG 2 and 5 kDa
Analyte No NP Fe [ng/ml] No‑vect. NPa Fe [µg] % of total Fe Vector. NPb Fe [µg] % of total Fe
Culture media <5 175.9 39.3 13.86 0.9
Wash buffer <5 48.23 10.8 18.73 4.2
Cytosol 9.55 1.18 0.3 1.41 0.3
Membrane 16.8 5.07 1.1 395.6 88.1
Nuclear <5 11.51 2.6 18.2 4.1
Cytoskeleton 5.04 205.90 45.9 11.45 2.6
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by subcutaneous or orthotopic injection of Panc-1 or 
SU.86.86 cells under the loose skin of the flank of the 
hind leg or into the pancreatic tail of nude nu/nu mice. 
The tumor size and body weight were monitored twice 
a week for 30–35 days. Four to five weeks post-injection 
of cells, orthotopic tumors had developed to a size of 
approximately 300–600  mm3 as assessed by ultrasound 
imaging. On average, each tumor bearing-mouse had 
a body weight of 25  g (min 22.5 and 27.2  g max) and 
showed no adverse behavior or cachexia. Subsequently, 
we performed comparative tumor targeting efficacy stud-
ies by dividing animals into three groups and applying 
NPs with three different properties.
Using a previously established NP dose adjusted to 
20 µg Fe in 150 µl NPs suspension the following regimens 
were administered by a single intravenous injection into 
the mouse tail: (i) non-targeted NPs (CAN-Mag@PNPs); 
(ii) tPA-pep1lac-decorated NPs (CAN-Mag@PNPs- 
tPApep-1lac) (iii) and tPA-pep1lac-decorated with outer 
shell REGAcp pegylated NPs (CAN-Mag@PNPs-PEG-
REGAcp-PEG/tPA-pep1Lac). As a proof of principle MRI 
was applied to assess the biodistribution and to visualize 
the target site accumulation (subcutaneous or orthotopic 
tumor) of the three types of NPs. The MRI was per-
formed at 5–8 min time intervals over a time period of 
1 h.
The MRI results showed that a single administration 
of vectorized NPs (CAN-Mag@PNPs- tPApep-1lac) is 
more efficacious in tumor deposition as compared to 
nontargeted control NPs (CAN-Mag@PNPs). The NP-
deposition was already 5 min post-injection detectable at 
both tumor inoculation sites but more pronounced in the 
orthotopic site (Fig. 5).
By comparing the ROIs voxels and their quotients 
between tumor and muscle of pre- and post-injection, we 
observed strong signal intensity (SI) quotient difference 
t/m of pre and post injection measured in subcutane-
ous and orthotopic tumors, indicating a satisfactory NP 
Fig. 4 Deshielding effect. a The CAN‑Mag@PNPs‑tPApep1Lac NPs bind to the receptors on the tumor cells. b The CAN‑Mag@PNPs‑PEG‑REGAcp‑
PEG/tPA‑pep1Lac NPs are hindered to interact with the tumor cells due to the protective outer PEG‑REGAcp‑PEG shell. c The CAN‑Mag@PNPs‑PEG‑
REGAcp‑PEG/tPA‑pep1Lac NP exposed to activated MMP‑9 release the outer shell and consequently the now accessible t‑PApep1lac vectors are able 
to bind to tumor cells. Flow cytometry analysis was carried out as described in the “Methods” section. The number in the lower right corner depicts 
the percentage of NP‑labeled cells
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accumulation in both tumor sites in the mice. The cor-
responding voxel quotients of pre and post NP-injections 
obtained from the T2-weighted images are presented in 
Table 6.
A tumor-specific and metalloprotease-dependent NP-
accumulation in the pancreatic tumor was observed 
by administration of vectorized NPs with outer shell 
REGAcp-PEGylated NPs (CAN-Mag@PNPs-PEG-
REGAcp-PEG/tPA-pep1Lac) shown in the bottom part 
of Fig. 5b. Here the measurable NP-deposition occurred 
in some mice with delay particularly in the orthotopic 
tumors, however, 50–60 min after NP-injection a consid-
erable retention in tumor was observed indicated as an 
intensity signal drop. One reason for this enhanced effi-
cacy may be that the targeted particles are designed to 
bind to the galectins Gal-1, Gal-3, Gal-4 proteins on pan-
creatic cancer cells or galectin-rich tumor-stroma, thus 
possibly delaying clearance from the site of the tumor. 
Additionally, in the tumor microenvironment, elevated 
and active MMP-9 have first to digest the outer protec-
tive shell of the NPs and make the tPApep-1lac ligands 
more accessible to the galectins. This proteolytic process 
may also be an explanation for the delayed deposition. 
Likely, the targeted NPs are also internalized after bind-
ing to cells, as demonstrated by previous Fe—uptake 
in vitro NPs exposure in cell culture. To confirm the MRI 
data we performed histological staining for iron (Prus-
sian blue stainings) of the excised tumors and the tissue 
and the slides were evaluated (Fig.  6). Indeed, we cor-
roborated enhanced iron deposition in NP-treated tumor 
samples.
Discussion
The use of targeted drug delivery systems can signifi-
cantly improve the therapeutic efficiency of small mol-
ecule chemotherapies by enhancing accumulation of the 
drugs in the tumor [20, 27–31]. As a positive follow-up of 
our previous report [32], we here explored the potential 
of vectorized biodegradable nanoparticles with an outer 
protective PEG shell cleavable by MMPs. Through this 
removable coating the NPs were less filtered out by the 
monocyte phagocytic system and resided for extended 
time in the blood circulation. An effective ligand directed 
delivery was achieved through the presence of MMP-9 
in the tumor microenvironment which specifically 
enhanced the NPs binding to tumor cell surface receptors 
Table 6 ROIs voxels quotients (entity/muscle) and  signal intensities loss for  organs of  interest after  administration 
of non-targeted and targeted NPs
a Values are mean signal intensities not normalized to muscle
Particle Entity SImean (entity)/SImean (muscle) Signal loss (1 − post/pre)
Pre (t = 0 min) Post (t = 5 min)
CAN‑Mag@PNPs Musclea 232 243 −4.74
Tumor sc. 3.11 3.21 −3.22
Tumor ot. 3.43 3.33 2.92
Liver 1.91 0.57 70.16
Kidney 3.06 3.25 −6.21
CAN‑Mag@PNPs‑tPA‑pep1Lac Muscle
a 249 196 21.29
Tumor sc. 3.52 3.21 8.81
Tumor ot. 3.18 2.41 24.21
Liver 1.33 0.38 71.48
Kidney 2.54 1.69 33.46
CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac Muscle
a 243 256 −5.36
Tumor sc. 3.89 3.42 12.08
Tumor ot. 4.57 3.85 15.75
Liver 1.81 0.37 79.56
Kidney 4.38 2.76 36.99
(See figure on previous page.) 
Fig. 5 MRI: a minor portion of the injected NPs reach the tumor. Axial presentation of subcutaneous (sc) and orthotopic (ot) Panc‑1 tumors 
T2‑weighted images of a single slice before (left) and 5 min after injection (right) of CAN‑Mag@PNPs (top); CAN‑Mag@PNPs‑tPApep1Lac (middle); 
and CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac NPs injection (bottom). The circled tumor areas represents the regions of interest (ROI) used for 
the analysis of signal intensity loss. The dashed circle areas are the muscle areas used as reference ROI. A signal drop (darker area) in the s.c. and ot. 
tumors can be seen after NP application in the T2 weighted images
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by de- shielding the NP and thus promoting the link-
age of NPs to cells by ligand-receptor interaction and 
improving tumor-to-normal NP-tissue deposition ratios.
In this study we used tissue plasminogen activator pro-
tein-derived peptides as ligands and the galectins as tar-
gets on pancreatic tumor cells. The binding properties of 
the selected t-PA peptide-1 to galectin-1 (Gal-1) differed 
and depended on several factors such as C- or N- termi-
nal fluorescence label and linkage of additional sugars 
as Gal-interacting molecules. Additionally to Gal-1, also 
Gal-3 and Gal-4 revealed to be good binding partners for 
the t-PA peptide-1. Applying IHC we confirmed the over-
expression of galectins (Gal-1, -3, -4) not only in human 
pancreatic cancer tissue sections but also in here inves-
tigated subcutaneous and orthotopic murine pancreatic 
tumor models.
As assessed by flow cytometry analysis, there was a dif-
ference in binding efficiency of the tPA peptides to galec-
tins depending on whether they were free or linked to 
nanoparticles. In general, free peptides bound to much 
higher degree to cells in comparison with t-PA-peptides 
decorated on NPs. Several of the selected t-PA peptides 
revealed stronger binding to Gal-1 in comparison with 
the native human t-PA protein. Enhancement of the 
binding to galectins Gal-1, Gal -3, Gal -4 by modifica-
tions of t-PA peptides was observed. Nevertheless, the 
t-PA peptide-1 outperformed others, particularly with a 
C-terminal linkage of fluorescein. Additional O-linked 
glycosylation of serine (S16) with lactose enhanced the 
binding up to 25-fold and, therefore, this glycopeptide 
was selected as the best binding partner (ligand) for Gal-
1, also for Gal-3 and Gal-4. Flow cytometry analysis was 
successfully used to test NPs stability and active targeting 
efficiency to pancreatic cancer cells. Depending on the 
physicochemical properties of the investigated NPs, and 
of exposure times, as well as used cell lines, the binding to 
cells varied between 35 and 90%. NP-modification, such 
as the cleavable outer PEG-shell, showed approximately 
threefold less interactions for PEG-REGAcp-PEGylated 
NPs, probably due to shielding the tPA- Gal interaction. 
In  vitro deshielding by addition of preactivated MMP-9 
enhanced the binding, however, the optimal in vitro con-
ditions were not reached.
In our in  vivo experiments, a good tolerance of the 
investigated bioactive nanoparticles (with and without 
PEG-REGAcp- PEGylation) after i.v. injection in nude 
mice was observed. Our tests of up to 48  h post injec-
tion showed no changes in physical conditions and 
behaviour. The delivery of NPs to solid tumors is known 
to be challenging due to (i) major uptake by the mac-
rophage phagocytosing system (MPS), for instance in the 
liver, and (ii) the poor penetration of the relatively large 
nanoparticles through the interstitial tumor microenvi-
ronment [33]. Here we investigated NPs with PEG for-
mulations that ranged in sizes between 110 and 130 nm. 
PEG is frequently used as coating material for modify-
ing the surface of NPs. PEG molecules form a protective 
hydrophilic layer with a negative zeta potential that helps 
to avoid recognition by the immune system, thereby 
reducing the rate of uptake of NPs by the MPS and 
extending their dwell time in the blood circulation [34]. 
Another important advantage of such PEG outer-shell 
decorated NPs is their accumulation in tumors due to an 
property termed the “enhanced permeability and reten-
tion effect” (EPR) [35]. The EPR depends upon irregular 
fenestration due to irregular lining of endothelial cells 
during the tumor neovascularization process. The irregu-
lar cell organization and leaky nature of the tumor vascu-
lature allows a selective retention of even larger particles 
(up to 500 nm) due to their proclivity to leak out of the 
blood vessel more readily than they can permeate back 
into the circulation. The EPR effect, initially described 
over two decades ago, is already successfully exploited in 
the nanomedicine field and led to re-engineering of con-
ventional chemotherapeutics. Paclitaxel is such an exam-
ple: by linking the drug taxol or the synthetic derivates to 
nanocore systems such as human serum albumin results 
Fig. 6 Evidence for uptake of vectorized NPs containing Fe2O3 
(maghemite) in pancreatic tumors in mice shown as Prussian blue 
staining. Post MRI the animals were sacrificed and tumors and organs 
of interest were excised for subsequent analyses of FFPE‑tissue sec‑
tions for Fe‑deposition (Prussian blue). Top Orthotopic (ortho.) tumor 
and subcutaneous (s.c.) tumor slices from a mouse ~ 1.5 h post injec‑
tion of CAN‑Mag@PNPs‑PEG‑REGAcp‑PEG/tPA‑pep1Lac (+NP). Bottom 
Ortho. and s.c. tumor slices from an untreated control mouse (−NP). 
400 × magnification; arrows indicate some nanoparticle deposition 
areas (blue spots)
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in Abraxane, a nanotechnology recently also applied for 
the treatment of pancreatic cancer [36]. However, many 
of these re-formulations are passive non-targeting deliv-
erers. Now more effort and focus is towards developing 
NP-formulations with properties possessing targeting 
carriers where the optimal binding activity is peritumoral 
or near the tumor cell due to e.g. proteolytic activity in 
the tumor microenvironment and by that enhancing NPs 
accumulation in tumor tissue and improving the tumor 
to normal tissue ratios [20].
For this purpose, we developed and tested such NPs 
(CAN-Mag@PNPs-PEG-REGAcp-PEG/tPA-pep1Lac). 
Here, as a proof of principle, we used a vectorized nano-
diagnostic without a warhead (therapeutic cargo of anti-
cancer drug) and were able to demonstrate that such 
particles are more efficiently deposed in pancreatic s.c. 
tumor models in comparison with NPs without outer 
shell [32]. Additionally, applying MRI we could demon-
strate that a more efficient NP deposition was observed 
in orthotopic tumors in comparison with the subcu-
taneous tumors. The orthotopic tumor model offers 
advantages over subcutaneous, because it can reflect the 
primary tumor microenvironment affecting blood supply, 
neovascularization, peritumoral inflammation and tumor 
cell invasion. Indeed, the investigated NPs ended up in 
the tumor, as demonstrated by the Fe-deposition in tis-
sues of pancreatic tumor models by Prussian blue indica-
tive for effective targeting. The higher NP accumulation 
in the orthotopic tumor model was likely due to the bet-
ter tumor vascularization, whereas in our subcutaneous 
model frequently a necrotic area in the tumor center was 
observed. That the site of cancer cell inoculation (here 
subcutaneous versus orthotopical) influences tumor vas-
cular permeability was previously reported [37].
Additionally as above mentioned, the permeability of 
the tumor vasculature is the consequence of an imbal-
ance between the formation and maturation of new blood 
vessels. This imbalance leads to a discontinuous joint 
between endothelial cells and results in inter-endothelial 
cell gaps forming a so called fenestrated endothelium or 
fenestrations facilitating the NP extravasation into the 
tumor stroma. Furthermore, by the liberation of the outer 
protective NP shield by MMP-9 and negative zeta-poten-
tial, the NPs were able to reside for a more prolonged time 
in the tumor cell vicinity, being retained by formation of 
t-PApep1lac-Gal complexes and probably not eliminated 
due to a compromised lymphatic drainage known to be 
impaired in tumors.
Conclusions
The in  vivo functionality of the investigated NPs 
depended on tumor cell-type and mouse model used, and 
on tumor inoculation area. An effective ligand directed 
delivery was achieved through the presence of proteases 
in tumor microenvironment which specifically enhanced 
the NPs binding to tumor cell surface receptors by de- 
shielding the NP and thus promoting the linkage of NPs 
to cells by ligand-receptor interaction and improving 
tumor-to-normal NP-tissue deposition ratios. The pref-
erential accumulation of NPs in the tumor vicinity raises 
the imaging sensitivity in MRI thus allowing imaging of 
already very small tumors (<0.5 cm3) of PDAC. The over-
lapping results (MRI and Fe-staining) with targeted NPs 
indicate a fast and enhanced deposition of NPs in the 
tumor. While further studies addressing the biodistribu-
tion and kinetics are needed to demonstrate the CAN-
Mag@PNPs-PEG-REGAcp-PEG/tPA-pep1Lac NPs real 
potential, this interlocking steps strategy of NPs delivery 
and deposition in pancreatic tumor is promising.
Methods
Cell lines
Human pancreatic carcinoma cell lines Aspc1, BxPc-3, 
Capan-1, MiaPaca-2, Panc-1, and Su.86.86 were obtained 
from American Type Culture Collection (Manassas, VA, 
USA). COLO-357 and T3M4 were a gift from R. Metz-
gar (Duke University, Durham, NC, USA). Cells were 
cultured in RPMI-1640 medium supplemented with 
10% fetal bovine serum (FBS), 100  U/ml penicillin, and 
100  µg/ml streptomycin (Invitrogen GmbH, Karlsruhe, 
Germany) at 37 °C in a humidified 5% CO2 atmosphere.
mRNA, cDNA, QRT‑PCR
All reagents and equipment for mRNA and cDNA prep-
aration were purchased from Roche Applied Science, 
Mannheim, Germany. mRNA was prepared by auto-
mated isolation using the MagNA Pure LC instruments. 
RNA was reverse transcribed into cDNA with the use of 
the 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) 
according to manufacturer’s instructions. QRT-PCR was 
performed with the Light Cycler Fast Start DNA SYBR 
Green kit. The number of specific transcripts was nor-
malized to the housekeeping gene cyclophilin B (CPB) 
and presented as copies/10,000 copies of CPB.
Protein isolation, SDS‑PAGE and Western Blot
Proteins from 80 to 90% confluent cells cultures were iso-
lated using the Pierce RIPA cell lysis buffer (ThermoSci-
entific, Germany) and the protein concentration of the 
lysates was assessed by Pierce BCA Protein Assay (Ther-
moScientific). Protein samples were heated for 10 min at 
95  °C and separated by SDS–polyacrylamide gel (10%) 
electrophoresis. After blotting to a nitrocellulose transfer 
membrane (Whatman, Dassel, Germany), a rabbit mono-
clonal antibody to galectin-1 (Acris 1:2000), or to control 
for equal loading mouse monoclonal antibody to GAPDH 
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(BD Pharmingen, Heidelberg, Germany; 1:2000) diluted 
in 5% BSA, 1× TBS and 0.1% sodium azide (Calbiochem/
Merck, Darmstadt, Germany) was added (at 4  °C over-
night). After washing, membranes were incubated with a 
goat anti-rabbit IgG POX, respectively, goat anti-mouse 
IgG POX (BD Biosciences, Heidelberg, Germany) as the 
secondary antibody (room temperature for 30  min). For 
detection, Amersham ECL plus Western Blotting Detec-
tion System (GE Healthcare, Munich, Germany) was used.
Analysis of biopsies
For IHC detection paraffin-embedded tissue sec-
tions (4 μm) were analyzed using the method previously 
described with some modifications [38]. Briefly, prior 
to antibody incubation, heat pretreatment in an antigen 
retrieval solution (DAKO Cytomation, Hamburg, Ger-
many; using citrate buffer (pH 6.1) was performed. Pri-
mary antibodies included mouse monoclonal antibodies 
to Gal-1 (diluted 1:200), mAb Gal-3 (diluted 1:1000) and 
mAb Gal-4 (diluted 1:250) all from Acris (Acris Antibod-
ies, Inc., San Diego, CA, USA) and were diluted in Anti-
body Diluent (DAKO North America, Inc., Carpinteria, 
CA, USA). EnVision  +  System-HRP, labeled polymer 
anti-mouse (Dako North America, Inc.) was used as sec-
ondary antibody. Isotype-specific negative controls to the 
primary antibodies (mouse IgG1 and mouse IgG2a, both 
DAKO Cytomation, Hamburg) were performed to detect 
the specificity of the antibodies.
In order to assess the iron oxide-loaded NPs deposi-
tion in pancreatic tumor tissue and liver in mice treated 
with NPs a post mortem qualitative approach was applied 
using the Prussian blue staining on histopathological 
formalin-fixed and paraffin-embedded (FFPE) tissue sec-
tions. Briefly the deparaffinized tissue sections were first 
incubated in a 10% solution of potassium ferrocyanide 
K4[Fe(CN)6] × 3H2O for 5 min. Subsequently the slides 
were incubated in a freshly prepared 1:2 mixture of 20% 
potassium ferrocyanide and 4% HCl allowing to react 
with the maghemite generating the dark blue complex 
Fe4[Fe(CN)6]3 × H2O so called Prussian blue. The slides 
were washed ×3 in distilled water and subsequently for 
5  min counterstained with a 0.1% nuclear fast red-alu-
minium sulfate solution (Roth, Karlsruhe, Germany).
t‑PA peptides and interaction studies with galectins
Tissue plasminogen activator (t-PA) which was already 
previously identified as a potential interacting ligand for 
Gal-1 was selected as vector moiety [8]. However, due 
to the limited t-PA-protein half-life time, we selected 
from the native t-PA protein four molecular probes 
(9–28 amino acids (AA) long peptides with areas carry-
ing N-linked glycosylation sides. The peptides derived 
from the human t-PA and selected as binding partners to 
Gal-1 were further designed (Tables 7, 8) and submitted 
for commercial larger scale synthesis to Peptide Synthesis 
Laboratories (PSL GmbH, Heidelberg, Germany). 
In order to investigate the binding properties of the 
modified t-PA-peptides [10-29 AA-long fluorescence-
labeled peptides] as ligands to galectins, the microscale 
thermophoresis (MST) (Monolith NT.115 MST instru-
ment, NanoTemper Technologies GmbH, Munich Ger-
many) technology was employed [39]. MST allows a 
quantitative analysis of protein interactions in solution 
and is based on the directed motion of molecules in tem-
perature gradients generated locally by an infrared laser, 
whereas the molecular mobility in the temperature gra-
dient is analyzed via fluorescence. MST is highly sensi-
tive to all types of binding-induced changes of molecular 
properties like protein size, charge, hydration shell or 
conformation. The binding modes such as dimerization, 
Table 7 Selected human tissue plasminogen activator (t-PA)-derived peptides used for the galectin interaction studies
a According position in the human tPA precursor (http://www.uniprot.org/uniprot/P00750)
Peptide # AA (n) Amino acid sequence Position in the t‑PAa‑protein MW [Da]
1 28 GTWSTAESGAECTNWNSSALAQKPYSGR 137–164 2959.3
2 27 CFNGGTCQQALYFSDFVCQCPEGFAGK 91–118 2920.2
3 27 YSSEFCSTPACSEGNSDCYFGNGSAYR 198–224 2902.1
4 9 CTSQHLLNR 476–484 1071.3
Table 8 t-PA-peptide-1 and its modifications used for the galectins Gal-1, -3, -4 interactions studies
Peptide 1 AA(n) Amino acid sequence MW [Da]
N 28 Fluo‑GTWSTAESGAECTNWNSSALAQKPYSGR‑COOH 3317.4
X: S(α‑galct.) 29 H2N‑GTWSTAESGAECTNWXSSALAQKPYSGRK‑TAMRA 3675.6
X: S(ßd‑lac.) 29 H2N‑GTWSTAESGAECTNWXSSALAQKPYSGRK‑Fluo 3742.6
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cooperativity, and competition are quantifiable and 
adaptable to diverse requirements of different biomol-
ecules. Therefore, MST turned out as an ideal method for 
the interaction studies of t-PA and t-PA-derived peptides 
with galectins.
The prescreening entailed selecting t-PA peptide1 (AA 
position 137-164) in the native t-PA for the manufacture 
of NPs for PDAC tumor targeting, which is described here. 
The 29  AA long sequence of the t-PApep1Lac is GTWS-
TAESGAECTNWXSSALAQKPYSGRK (where X stands 
for Ser(β-d-lactose). By using the free amino- and carboxyl-
terminal groups of the peptide, the linkage with NPs can be 
performed. The side chain of the C-terminal lysine (K) is 
additionally fluorescein-linked for monitoring studies.
Synthesis and characterization of t‑PA‑vectorized 
nanoparticles
Most of the specific chemicals and reagents (analyti-
cal grade and/or highest purity level) used for manufac-
turing and surface modification of γ-Fe2O3 maghemite 
(CAN-Mag) NPs i.e., FeCl3·6H2O, FeCl2·4H2O, NH4OH 
(28–30%), chitosan (50–190  kDa), divinylsulfone (DVS), 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) 
have been purchased from Sigma-Aldrich (Israel) and 
used without any further purification. Monoelectronic 
CAN [CeIV(NH4)2(NO3)6] oxidant was purchased from 
Acros Organics. Reactive functional PEGs (methoxy-
PEG amine 2 and 5 kDa, PEG diamine 2 and 5 kDa and 
methoxy-PEG vinylsulfone 5 kDa) were purchased from 
JenKem Technology USA Inc.
tPA peptide (MW 3742.6) with a full name Pep1N16(S(β-
d-Lact)), with the amino-acid sequence GTWSTAES-
GAECTNWXSSALAQKPYSGRK (X  =  Ser-β-d-Lact), 
and with fluorescein on the K29 side-chain and with a free 
C-terminal group was purchased from PSL GmbH, Hei-
delberg, Germany. Amicon® Ultra 15 ml 100 kDa centrifu-
gal tubes were purchased from Merck Millipore.
Transmission electron microscopy
Both sizes and shapes of functional nanoparticles were 
obtained by using a transmission microscopy (FEI Tec-
nai Spirit Bio-Twin, Oregon, USA) equipped with a CCD 
1 ×  1 k camera (Gatan). Samples for TEM imaging were 
prepared by placing a drop of diluted H2O dispersion (200–
250 μg/ml) onto a 400-mesh copper TEM grid (400C-FC, 
Electron Microscopy Sciences, Hatfield, PA, USA) and then 
drying in a vacuum chamber at ambient temperature.
Nanocarrier fabrication—experimental procedure 
towards starting near neutral magnetite (Fe3O4) 
nanoparticles
This experimental procedure has been already published 
and described previously [15]. A solution of FeCl3·6H2O 
(240.0  mg, 0.9  mmol) dissolved in deoxygenated milliQ 
purified H2O (4.5 ml) was mixed with an aqueous solution 
of FeCl2·4H2O (97.5  mg, 0.45  mmol, 4.5  ml H2O). This 
solution was kept under N2 and ultrasonicated (bath soni-
cator) for 5–10 min at room temperature. Then, a concen-
trated 24 wt% aqueous NH4OH (0.75 ml) was introduced 
in one shot, resulting in an immediate black precipitation 
of magnetite (Fe3O4) NPs. Ultrasonication was then con-
tinued for 10 additional minutes. Resulting Fe3O4 NPs 
were transferred into a glass bottle (100 ml), magnetically 
decanted (using a strong external magnet), and washed 
with ddH2O (3 ×  40  ml) until neutrality. Then, brilliant 
black free flowing magnetite (Fe3O4) NPs were stored as a 
30 ml NPs suspension in ddH2O for 2 h at room tempera-
ture before any further processing/surface engineering.
Nanocarrier fabrication—experimental procedure 
towards functional CAN‑Mag‑Chitosan NPs (chitosan 
decoration by injection method)
The former aqueous magnetite NPs suspension (60  ml) 
was magnetically decanted to separate the magnetite 
(Fe3O4) NPs from its aqueous storage phase. Ceric ammo-
nium nitrate (CAN, (NH4)2Ce(IV)(NO3)6, 300.0  mg, 
0.547  mmol) dissolved in 12.0  ml MeCOMe was then 
introduced into decanted magnetite NPs followed by the 
addition of degassed milliQ purified H2O (12.0  ml). The 
corresponding medium mixture was ultrasonicated using 
a high-power sonicator (Sonics®, Vibra cell, 750 Watt, 
power modulator set-up at 25%) equipped with a titanium 
horn (45  min, 0  °C) under an inert argon atmosphere. 
Then, a slightly acidic chitosan solution (7.5 ml, 8.0 mg/
ml) was added while ultrasonication was maintained for 
15 additional minutes under these same conditions. Thus, 
the resulting highly stabilized hydrophilic CAN-Mag-Chi-
tosan NPs were cleaned [washing with ddH2O (3 × 10 ml) 
using an Amicon® Ultra-15 centrifugal filter devices 
(100 K) processed at 4000 rpm during 5–6 min (rt, 18 °C) 
and re-dispersed in ddH2O (10 ml).
Nanocarrier fabrication—experimental procedure for PEG 
attachment onto CAN‑Mag‑Chitosan NPs
The previously prepared and purified CAN-Mag-Chi-
tosan NPs were analysed for weight concentration deter-
mination by freeze-drying a known volume (0.5 ml) of the 
NPs suspension in 2 ml polyethylene tubes and by weigh-
ing masses before and after sample loading. PEG-NH2 
(2 or 5  kDa, 36.0  mg) and NH2-PEG-NH2 (2 or 5  kDa, 
18.0  mg) were then added to CAN-Mag-NPs (10.0  mg, 
3.0 ml), followed by the addition of divinylsulfone (DVS, 
2.0 μl) that served as a bifunctional Michäel-reactive 
linker for both NPs surface and PEG species amines. 
Therefore, the reaction medium was shaken overnight 
at room temperature (RT). The resulting PEG-modified 
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NPs were then washed/cleaned using dialysis membranes 
(12–14 kDa).
Nanocarrier fabrication—experimental procedure for t‑PA 
decoration of surface‑modified CAN‑Mag NPs
In the next NPs functionalization step, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC, 0.77  mg, 
4.0  mmol, 0.5  ml) was added to the tPA peptide solu-
tion (0.5  mg, 0.5  ml). After 10  min reaction (RT) for 
COOH chemical group activation, the tPA/EDC solution 
was added to filtered (nylon 0.22  μm) surface-modified 
CAN-Mag-Chitosan or CAN-Mag-Chitosan-PEG NPs 
(10.0  mg, 3.0  ml) and the reaction medium was shaken 
overnight at RT. For resulting NPs purification step com-
pletion, the resulting functional t-PA-decorated NPs have 
been washed by processing in Amicon® Ultra-15 centrif-
ugal filter tubes (2 × 10 ml).
Nanocarrier fabrication—experimental procedure 
towards functional CAN‑Mag@PNPs
Poly(d,l-lactide-co-glycolide) (50/50) with carbox-
ylic acid end group (PLGA-COOH, inherent viscos-
ity 0.12 dl/g, MW  ~7  kDa) has been purchased from 
Lakeshore Biomaterials (Birmingham, AL, USA). Poly-
ethylene glycol with both amino and carboxylic acid 
end groups (NH2-PEG-COOH/NH2, MW  ~3  kDa) has 
been purchased from Rapp Polymere GmbH (Tübingen, 
Germany). PEG_REGAcp_PEG substrate [PEG3400-Gly-
Gly-Gly-Glu-Arg-Gly-Pro-Pro-Gly-Pro-Gln-Gly-Ala-
Arg-Gly-Phe-HyP-Gly-Thr-Pro-Gly-Leu-PEG5000-NH2 
(10.2  kDa, HyP  =  (2S,4R)-4-hydroxy Pyrrolidine-2-car-
boxylic acid) was purchased from Anaspec Inc. (Fremont, 
California, USA).
DLS measurements were performed on a Malvern 
Zetasizernano-S system with a 532  nm laser beam. 
ζ potential measurements were conducted using 
DTS1060C-Clear disposable zeta cells at 25  °C. Spec-
traAA 100 Varian was used for atomic absorption 
spectroscopy (AAS) analyses. Intradermal air pouch leu-
cocytosis was applied as an in vivo the quality control for 
biocompatibility, toxicity and inflammatory response and 
the results of the core NPs were previously reported [40].
Nanocarrier fabrication—experimental procedure 
towards CAN‑Mag@PNPs conjugated with t‑PA1Lac and/or 
PEG‑REGAcp‑PEG species
The maghemite-loaded PLGA-PEG-COOH based poly-
meric nanoparticles (CAN-Mag@PNPs) were prepared 
according to a procedure already reported by us [24]. 
Brefly, the original CAN-maghemite nanoparticles in 
water were added to an ethanol solution containing 
the organic ligand ethyl 12-([3,4-dihydroxyphenethyl]
amino)-12-oxododecanoate. The mixture was kept in an 
ultrasound bath for 1  h, then left to react overnight at 
room temperature under mechanical stirring. Afterward, 
the solution was decanted magnetically and washed with 
ethanol before redispersion of the lipophilic obtained 
nanoparticles in acetone.
To 10 ml of the acetone solution a total of 100 mg of the 
copolymer PLGA-b-PEG-COOH (10  kDa) was added. 
This organic phase was mixed to 100 ml of water under 
vigorous stirring, maintaining the water/organic ratio of 
10/1 with constant removal of the resulting solution. The 
final mixture was kept for 30  min under vigorous stir-
ring. The residual organic solvent was evaporated under 
reduced pressure. The solution of the obtained CAN-
Mag@PNPs was concentrated to a volume of 10 ml using 
a tangential flow filter (Pellicon XL filter device, Biomax 
membrane with 500.000 NMWL; Millipore Corporation) 
following by filtration using a syringe filters SterivexTM-
GP of polyethersulfone (0.22 μm, Millipore Corporation).
For the conjugation of t-PA1Lac peptide and/or PEG-
REGAcp-PEG the following procedure was adopted: a 
water solution (10  ml) of CAN-Mag@PNPs containing 
approximately 4  µmol of COOH functions was mixed 
with 10 ml of PBS 0.01 M solution. 1-Ethyl-3-(3-dimeth-
ylaminopropyl)carbodiimide hydrochloride (EDC·HCl, 
4 µmol, 0.77 mg) and N-hydroxysulfosuccinimide (Sulfo-
NHS, 4 µmol, 0.86 mg) were added and the solution was 
shaken for 1 h at room temperature. Then tPA1Lac pep-
tide (0.129  µmol, 0.5  mg) and/or PEG-REGAcp-PEG 
(0.06  µmol, 0.64  mg) were added to the reaction mix-
ture, which was allowed to shake for an additional 24 h. 
The resulting nanosystem was washed with PBS 0.01 M 
(3  ×  10  ml) using centrifugal (3000  rpm, 10  min each 
cycle) filter devices (Amicon Ultra, Ultracel membrane 
with 100.000 NMWL, Millipore, USA) and finally fil-
trated through Sterivex filter (0.22 µm). The final volume 
was adjusted to 5 ml.
Flow cytometry
Flow cytometry (fluorescent-activated cell sorting/
FACS) analysis was used to determine the binding of 
fluorescein-labeled t-PA-pep1Lac and t-PApep1-vector-
ized nanoparticles (CAN-Mag@PNPs-tPApep1Lac and 
CAN-Mag@PNPs-PEG-REGAcp-PEG/tPA-pep1Lac) 
on the surfaces of Panc-1 and SU.86.86 cells. Additional 
FACS analyses were performed to monitor concentra-
tion and time-dependent binding efficiency and changes 
caused by addition of competitors (galactose, lactose) 
or in the presence of active MMP-9, which cleaves the 
REGAcp sequence. Deshielding of CAN-Mag@PNPs-
PEG-REGAcp-PEG/tPA-pep1Lac was carried out by 
pre-activated MMP-9 (20  µM proMMP-9 and 200  nM 
of catalytic domain cdMMP-3 in 100 mM Tris, 100 mM 
NaCl, 10 mM CaCl2, pH 7.4 for 2 h at 37 °C). The active 
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MMP-9 (50  µl, 10  µM) was incubated in the presence 
of 450 µl NPs and subsequently added to cells. Nano-
particle-exposed cell monolayers (of 2  ×  105 cells/2  ml 
medium in 6 well plates), with or without treatment, 
were harvested 2, 12, 24  h post-exposure using 1  mM 
EDTA–phosphate-buffered saline (PBS) detachment 
buffer, (Miltenyi GmbH, Bergisch Gladbach, Germany), 
washed 3 times in PBS, incubated for 45 min on ice and 
subsequently subjected to analysis in a BD™ LSR II flow 
cytometer and Software Program: BD FACSDiva 7.0 
(Becton–Dickinson,)
Iron uptake
For the determination of NP binding and uptake in 
Panc-1 and Su.86.86 cells the culture medium of a T-75 
flask at 80–90% cell culture confluency cells (3–4 × 106 
cells) was replaced by PBS and the cells were exposed 
for 2, 4 and 6  h to NP with an iron content of 500–
600 µg Fe/T75 flask. Two sets of NPs were used: CAN-
Mag-Chitosan (non-targeted) and the corresponding 
CAN-Mag-Chitosan-t-PApep1Lac (targeted). After NP-
exposure the cell culture supernatants were collected 
and the adherent cells were processed in a wash buffer 
and the subcellular fractions were performed using the 
ProteoExtract™-kit (Calbiochem/Merck, Darmstadt, 
Germany) for the isolation of subcellular compart-
ments (membrane, cytoplasm, nucleus, cytoskeleton), 
according to the manufacturer’s recommendation. The 
collected cell culture supernatants and fractions were 
transferred into glass flasks, dried for 72 h at 80 °C and 
subsequently processed for Fe-determination with 2 ml 
65% HNO3 and 250 µl 30% H2O2. The inorganic residues 
were resuspended in 1 ml 2% HNO3 and the Fe-content 
was determined by inductively coupled plasma-optical 
emission spectrometry using Agilent ICP-OES 720 (Agi-
lent Technologies, Santa Clara, CA).
Tumor mouse models
For the subcutaneous (s.c.) tumor model ~2 × 106 Panc-
1-cells resuspended in 50  µl PBS were injected subcu-
taneously into the posterior region of the mouse trunk 
of female 5 to 6-week-old CD®nuBR mice (crl:CD1-
Foxn1nu) Charles River Laboratories, Sulzfeld, Germany) 
through a 26-gauge needle. The injection sites were 
examined daily. Ten days post-injection the appearing 
tumors were measured twice weekly using a caliper and 
the volumes were calculated with the formula for ellip-
soids (V = 4/3 π × (width/2)2 × (length/2)2.
For the orthotopic (ortho) tumor model tumor cell 
inoculation was performed by direct injection of tumor 
cells in the pancreatic tail of 5 to 6-week-old female 
CD®nuBR mice according to the procedure previ-
ously described in detail [32]. Briefly, a laparotomy was 
performed, the spleen with tail of the pancreas was exte-
riorized with cotton swabs, and with an insulin syringe 
27G  ×  1.2 in., 1.0  ml (Terumo, Eschborn, Germany) 
approx. 2 × 106 cells in 20 µl PBS of cell lines Panc-1 or 
Su.86.86 were gently injected into the pancreatic paren-
chyma. After completion of the surgical procedure, mice 
were inspected daily, the wound healing, body weight 
and physical condition of the animals was monitored 
over the total experimental time. Tumor growth was 
assessed by high-frequency ultrasound imaging, with 
a Vevo 770® High-Resolution Imaging System, (Visual 
Sonics, Amsterdam, Netherlands).
The subcutaneous and orthotopic tumors were allowed 
to grow for about 4–5 weeks until approximately 0.5 cm3 
in size. When the in vivo experiments were finished, ani-
mals were sacrificed and tumors and organs of interest 
were excised, divided into one part for flash- freezing in 
liquid N2 and storage at −80 °C for subsequent analyses 
and the other part for formalin-fixing and embedding in 
paraffin wax for histopathology analysis, IHC and Prus-
sian blue staining.
Magnetic resonance imaging
Relaxation measurements where performed using a 
1.5  Tesla generally available human whole-body MR-
scanner (Siemens Magnetom Symphony, Erlangen, Ger-
many) with a radiofrequency coil/resonator optimized 
for animals for signal reception. The mouse coil was 
designed as a cylindrical volume resonator with an inner 
diameter of 35 mm and a usable length of 100 mm. For 
body temperature control the resonator was integrated in 
a spiral tube water jacket maintained at 37 °C.
For MRI examination and catheterization, tumor bear-
ing female mice were anesthetized by inhalation of a mix-
ture of isofluorane (1.5%), and O2. The flow was adjusted 
to the individual need of the animal. The tail vein was 
catheterized using a 30 G needle connected to a 10 cm PE 
10 fine bore 0.28 mm ID; 0.61 mm OD polyethylene cath-
eter (Smiths Medical International Ltd., Kent, UK) filled 
with 0.9% NaCl. Successful puncture of the tail vein was 
controlled by blood reflux into the catheter and by injec-
tion of 30  µl  0.9% NaCl. Subsequently the 1  ml syringe 
with 0.9% NaCl was replaced by a NPs containing syringe 
and the mouse with the tail-fixed catheter and syringe 
was placed into the animal resonator. Between 130 and 
150  µl of NPs (10  mg/ml), respectively, were manually 
injected as bolus within 10–15 s into the tail vein of the 
nude mice.
All animals were examined with multiple axial high-reso-
lution T2w turbo spin echo (TSE) pulse sequences, using the 
following imaging parameters: TR = 4390 ms, TE = 60 ms, 
TA =  7:38, NA =  5, field of view =  40 ×  54 ×  55  mm2, 
matrix = 144 × 192 × 46, slice thickness = 1.20 mm, voxel 
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size =  0.28 ×  0.28 ×  1.20  mm3. During an overall meas-
urement time of ~65 min, 8 measurements were obtained. 
Slices were placed to cover the liver, kidneys, muscle (the 
norm), the subcutaneous (sc) tumor, and the orthotopic (ot) 
tumor. The tissue types were analyzed in terms of the tem-
poral behavior of the signal intensity.
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